The Week Ahead: COS...
Health Care: Drugs
Arrowhead Research Corporation (ARWR: NASDAQ)
$2.18 0.03 | 1.40%
05/24/13 - 04:00 PM ET
Company Cash Flow
| Sep 2012 | Sep 2011 | Sep 2010 | Sep 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -21.13M | -3.49M | -5.77M | -19.31M |
| Operating Gains/Losses | -198.48K | 424.40K | -10.88K | -1.35M |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -775.32K | -736.25K | -783.43K | -60.66K |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | -6.85K | 18.47K | -114.83K | 0.00 |
| (Decrease) Increase In Payables | 291.88K | 157.08K | -331.72K | -328.72K |
| (Decrease) Increase In Other Current Liabilities | 1.07M | 468.59K | 81.74K | -644.98K |
| (Increase) Decrease In Other Working Capital | -23.75K | 0.00 | 74.91K | 144.64K |
| Other Non-Cash Items | 4.01M | -4.85M | -1.57M | 5.21M |
| Net Cash From Continuing Operations | -15.34M | -7.66M | -7.70M | -15.28M |
| Net Cash From Discontinued Operations | -280.00 | 2.27M | -2.66K | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -15.34M | -5.39M | -7.70M | -15.28M |
| Sale of Property, Plant & Equipment | 290.31K | 0.00 | 63.00K | 79.38K |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Property, Plant & Equipment | -479.71K | -9.67K | -5.41K | -40.24K |
| Acquisitions | 121.03K | -1.70M | 0.00 | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | 440.64K | -175.38K | 487.59K | 739.13K |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 2.52M |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 10.97M | 6.23M | 12.17M | 4.76M |
| Repayment of Long-Term Debt | -196.61K | 0.00 | -726.53K | -810.46K |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 0.00 | 600.00K | 0.00 |
| Net Cash From Financing Activities | 10.77M | 6.23M | 12.04M | 6.47M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | -4.13M | 660.23K | 4.83M | -8.07M |
Portfolios with ARWR
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- Usertest1123
- ContributorStocks Under-$10 Setting Up...
- UserKJP 2012 Carbon Flash Fund
- Contributor8 Penny Stocks Get Delistin...
- UserWilliam T Blanchard - Medical
- UserCaroline
- UserSimon $9000
- Usertreneehill's pennies
Latest ARWR Headlines from TheStreet
- 5 Stocks Under $10 Set to Soar 02.28.13 | 01:02 pm
- 4 Biotech Stocks Under $10 Moving Higher 02.20.13 | 09:02 pm
- 5 Stocks Under $10 Set to Trade Higher in November 11.01.12 | 01:11 pm
- Arrowhead's Management Presents At 2012 Wedbush PacGrow Life Sciences Management Access Conference (Transcript) 08.14.12 | 09:08 pm
- Arrowhead Research Corporation's CEO Discusses F3Q12 Results - Earnings Call Transcript 08.13.12 | 08:08 pm
- Arrowhead Research's CEO Hosts Alvos Acquisition Conference Call (Transcript) 05.08.12 | 12:05 am
- 6 Stocks Hitting New 52-Week Highs 11.10.11 | 01:11 pm
- 8 Penny Stocks Get Delisting Warning 01.04.11 | 07:01 am
- Arrowhead Research CEO Discusses F4Q2010 Results  Earnings Call Transcript 12.22.10 | 09:12 pm
- Arrowhead Research Corp. F3Q10 (Qtr End 06/30/10) Earnings Call Transcript 08.12.10 | 06:08 pm
Press Releases for ARWR
- Arrowhead Induces 90% Reduction In Hepatitis B Antigens In Chimpanzee With Chronic Infection: Data Follow Previous Report Of Reduction In Viral DNA - Business Wire 03.25.13 | 07:03 am
- Arrowhead RNAi Candidate ARC-520 Induces Greater Than 90% Reduction In Circulating HBV DNA In Chimpanzee With Chronic Hepatitis B - Business Wire 03.14.13 | 07:03 am
- Arrowhead To Host Analyst Event In New York To Discuss RNAi-based Hepatitis B Candidate ARC-520 - Business Wire 03.07.13 | 07:03 am
- Arrowhead Receives Notice Of Patent Allowance For New Protease Sensitive Masking Chemistry For DPC SiRNA Delivery System - Business Wire 02.28.13 | 07:02 am
- Arrowhead Data Demonstrates RNAi Candidate ARC-520 Silences Hepatitis B Virus - Business Wire 02.26.13 | 09:02 am
- Arrowhead Reports Fiscal 2013 First Quarter Financial Results - Business Wire 02.13.13 | 04:02 pm
- Lifshitz Law Firm Announces Investigation Of Arrowhead Research Corp., MEI Pharma, Inc., Park City Group, Inc., And The Toro Company - PR Newswire 02.07.13 | 05:02 pm
- Arrowhead To Report Fiscal 2013 First Quarter Financial Results - Business Wire 02.06.13 | 07:02 am
- Arrowhead To Present At Upcoming Scientific Conferences - Business Wire 02.01.13 | 07:02 am
- Arrowhead Announces Pricing Of A Public Offering Of Common Stock And Warrants - Business Wire 01.25.13 | 09:01 am
Partner Headlines for ARWR
- Arrowhead Research Receives Notice of Patent Allowance for New Formulation of DPC siRNA Delivery System Showing 500-Fold Increase in Potency - Benzinga 10.16.12 | 09:10 am
- Arrowhead Sells 2.3M Shares, 1.7M Warrants for $6.2M - Benzinga 08.13.12 | 09:08 am
- Anti-Obesity Drug CAUSES Trouble for Arrowhead and 4 Stocks that Have Hit 52-Week Lows - Wall St. Cheat Sheet 06.27.12 | 10:06 am
- 4 Smaller Alternatives to Big Pharma Obesity Treatments - Benzinga 05.25.12 | 01:05 pm
- Tekmira: RNAi Company With Long Term Potential, Short Term Catalysts - Seeking Alpha 03.07.12 | 08:03 am
- Arrowhead Reports Q1 EPS of $(0.02) - Benzinga 02.10.11 | 04:02 pm
- UPDATE 1-Arrowhead co, Smith & Nephew to make cartilage product - Reuters 10.18.10 | 08:10 am
